TBCE and cholangiocarcinoma: IL-6 is increased in the serum of patients with CCA and is a target molecule of CCA.33 Our data show that during DEN-treated CCA progression, IL-6 expression is upregulated in cholangiocytes, KCs, HSCs, and hepatocytes.